Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.
By Roland Leclercq. Clinical Infectious Diseases, 2002
742 citations recorded by the source corpus.
Subfields: Epidemiology, Pharmacology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/5e8d1fd68b7db69cae82ba867a7e71fe1c23a9b8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
- Hazel A. Barton
- M. Johnston
- A. Alanis
- Gerard D. Wright
- Kirandeep Bhullar
- Andreas G. Tofarides
- Andrew C. Pawlowski
- Nicholas Waglechner
In Pharmacology
- Hazel A. Barton
- M. Johnston
- A. Alanis
- Gerard D. Wright
- Kirandeep Bhullar
- Andreas G. Tofarides
- Andrew C. Pawlowski
- Nicholas Waglechner
In Pulmonary and Respiratory Medicine
- Hazel A. Barton
- M. Johnston
- A. Alanis
- Gerard D. Wright
- Kirandeep Bhullar
- Andreas G. Tofarides
- Andrew C. Pawlowski
- Nicholas Waglechner
Citations in the corpus
- Mechanisms of Antibiotic Resistance (2016, neutral): “Since macrolides, lin-cosamides, and streptogramin B antibiotics have over-lapping binding sites in the 23S rRNA, expression of the erm genes confers cross-resistance to all members of the MLS B group (62, 63).”
- The evolution of Staphylococcus aureus. (2008, neutral): “1) (Ito et al., 2001, 2003; Leclercq, 2002; Oliveira et al., 2006a; Takano et al., 2008).”
- Antibiotic Resistance Is Prevalent in an Isolated Cave Microbiome (2012, positive): “Phosphorylation of macrolides in pathogenic bacteria is a growing clinical problem [38] catalyzed by a family of macrolide phosphotransferases (MPHs) [36,39].”
- Antimicrobial Resistance in Bacteria: Mechanisms, Evolution, and Persistence (2019, positive): “23SrRNA mutations have also been implicated in the development of macrolide, lincosamide, and streptogramin B resistance (Leclercq 2002).”
- The molecular evolution of methicillin-resistant Staphylococcus aureus. (2007, neutral): “1) [5,6].”
- Azithromycin: mechanisms of action and their relevance for clinical applications. (2014, neutral): “Mef transporter (effluxpump) expression typically results in a lower level of specific resistance towards 14- and 15-membered macrolide antibiotics (MICs 4–32 ug/mL) and this type of resistance is referred to as the M phenotype (Leclercq, 2002).”
- Efflux-mediated antimicrobial resistance. (2005, neutral): “While most Gramnegative bacteria and the mycobacteria are generally resistant to these agents, there are notable exceptions (macrolide susceptibility of mycobacteria(144) and macrolide/lincosamide susceptibility of Bordetella, Campylobacter, Chlamydia, Helicobacter, Legionella, Neisseria, Haemophilu”
- Pulsed-Field Gel Electrophoresis Typing of Oxacillin-Resistant Staphylococcus aureus Isolates from the United States: Establishing a National Database (2003, neutral): “anism was assumed to be efflux of the macrolide via msrA (35).”
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. (2012, neutral): “aureus isolate is considered non-susceptible to all lincosamides when it tests non-susceptible to clindamycin [51,53].”
- Resistance to antibiotics: are we in the post-antibiotic era? (2005, positive): “Efflux was first described for tetracycline and macrolide antibiotics (55,56) but is now common for many other antibiotics such as fluoroquinolones (52,54).”